Combining magnetic resonance (MR)-guided focused ultrasound with microbubbles and immune checkpoint inhibitors (ICIs) could transform non-small cell lung cancer (NSCLC) treatment by reducing radiation side effects and increasing intracranial response rates, according to Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida.
These findings were presented at the American Society of Clinical Oncology (ASCO) 2025 meeting as part of the LIMITLESS trial.
